Contact SCGE
Your email
Message
Send
SCGE Consortium Home
About SCGE TCDC
Contact Us
License
Home
Gene Therapy Trial Browser
Clinical Trial Report
Gene Therapy Trial Report
Summary
An Exploratory Clinical Trial Evaluating LX109 Gene Therapy in Patients With nAMD
NCTID
NCT06022744
(View at clinicaltrials.gov)
Description
To evaluate the safety and tolerability of intravitreal injection of LX109 in patients with nAMD.
(Show More)
Development Status
Active
Indication
Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
Disease Ontology Term
DOID:10871
Compound Name
LX109
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Funder Type
Other
Recruitment Status
Not yet recruiting
Enrollment Count
12
Results Posted
Not Available
Therapy Information
Target Gene/Variant
Undisclosed
Therapy Type
Undisclosed
Therapy Route
In-vivo
Mechanism of Action
Undisclosed
Route of Administration
Intravitreal
Drug Product Type
Viral vector
Target Tissue/Cell
Delivery System
Viral transduction
Vector Type
undisclosed
Editor Type
Dose 1
7E9 vg/eye
Dose 2
3.5E10 vg/eye
Dose 3
Dose 4
Dose 5
Study Record Dates
Current Stage
Na
Submit Date
2023-08-28
Completion Date
2027-09-30
Last Update
2023-09-05
Participation Criteria
Eligible Age
>=50 Years
Standard Ages
Adult, Older adult
Sexes Eligible for Study
ALL
Locations
No.of Trial Sites
Locations
Regulatory Information
Has US IND
False
FDA Designations
Recent Updates
Resources/Links
Resources/Links
No External Links Available.